Assenagon Asset Management’s Royalty Pharma RPRX Stock Holding History

Assenagon Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27M	Buy	22,668 +3,226	+17%	+$168K	﹤0.01%	933
2026 Q1	$933K	Buy	19,442 +669	+4%	+$29.3K	﹤0.01%	904
2025 Q4	$725K	Hold	18,773	–	–	﹤0.01%	1003
2025 Q3	$662K	Buy	18,773 +1,083	+6%	+$39.2K	﹤0.01%	1004
2025 Q2	$637K	Sell	17,690 -804	-4%	-$26.6K	﹤0.01%	1000
2025 Q1	$576K	Sell	18,494 -574	-3%	-$18.2K	﹤0.01%	993
2024 Q4	$486K	Buy	+19,068	New	+$506K	﹤0.01%	1203

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management's RPRX Position: Q2 2026 in Review

Assenagon Asset Management increased its Royalty Pharma (RPRX) stake by 17% in Q2 2026, buying an estimated $168K and bringing the position to 22,668 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Assenagon Asset Management first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Assenagon Asset Management held 22,668 shares of Royalty Pharma worth $1.27M as of Q2 2026.
Assenagon Asset Management bought 3,226 Royalty Pharma shares in Q2 2026, an estimated $168K.
Royalty Pharma made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #933 holding.
Assenagon Asset Management first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.